ABBOTT LABORATORIES Q1 FY26 Results

Summary

Abbott reported first-quarter 2026 sales of $11,164 million, marking a 7.8 percent increase on a reported basis and 3.7 percent on a comparable basis compared to the prior year. Adjusted diluted earnings per share grew by 6 percent to $1.15, while GAAP diluted EPS stood at $0.61. A significant highlight of the quarter was the completion of the Exact Sciences acquisition, which strategically positions Abbott as a leader in oncology diagnostics. Looking ahead, management projects full-year 2026 comparable sales growth between 6.5% and 7.5% and adjusted diluted EPS in the range of $5.38 to $5.58, despite a $0.20 dilution from the recent acquisition. CEO Robert B. Ford expressed confidence in delivering accelerating growth throughout the year, noting the results were aligned with expectations.

Key Highlights

1. 1

   Abbott's first-quarter GAAP diluted EPS was $0.61, while adjusted diluted EPS grew by 6 percent to $1.15.

2. 2

   Total first-quarter sales increased by 7.8 percent on a reported basis to $11,164 million and by 3.7 percent on a comparable basis.

3. 3

   The company completed the acquisition of Exact Sciences on March 23, 2026, establishing Abbott as a leader in the fast-growing oncology diagnostics market.

4. 4

   Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the Exact Sciences acquisition.

5. 5

   Worldwide Medical Devices sales increased 13.2 percent on a reported basis and 8.5 percent on a comparable basis in the first quarter, driven by double-digit growth in Electrophysiology, Heart Failure, and Rhythm Management.

6. 6

   Established Pharmaceuticals sales demonstrated strong performance, increasing 13.2 percent on a reported basis and 9.0 percent on a comparable basis, led by double-digit growth in Key Emerging Markets.

7. 7

   Abbott declared its 409th consecutive quarterly dividend of $0.63 per share, payable on May 15, 2026.